Literature DB >> 20308040

Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease.

Thurid Ahlenstiel1, Lars Pape, Jochen H H Ehrich, Martin K Kuhlmann.   

Abstract

BACKGROUND: Hyperphosphataemia in patients with chronic kidney disease (CKD) is associated with mineral and bone disorder and increased cardiovascular mortality. Despite phosphate binders (PB), nutrition counselling and dialysis therapy, the prevalence of hyperphosphataemia remains unacceptably high. It was hypothesized that an inadequate relation of PB dose to meal inorganic phosphorus (iP) content may be an important factor for failure of phosphate management.
METHODS: The innovative 'Phosphate Education Program' (PEP) bases on patient empowerment to eye-estimate meal iP content by newly defined 'Phosphate Units' (PU; 1 PU per 100 mg phosphorus) and self-adjust PB dosage to dietary iP intake by an individually prescribed PB/PU ratio (PB pills per PU). In a prospective study, 16 children (aged 4-17 years) with CKD and their parents were trained with the PEP concept and followed up for 24 weeks for changes in serum electrolyte levels, dietary behaviour and PB dose.
RESULTS: Within 6 weeks after PEP training, the percentage of children with serum phosphate (PO) >1.78 mmol/l dropped from 63% (10/16) to 31% (5/16). Mean serum PO level decreased from 1.94 ± 0.23 at baseline to 1.68 ± 0.30 (SD) mmol/l in Week 7-12 (P = 0.02) and to 1.78 ± 0.36 (SD) mmol/l in Week 19-24 (P = 0.2), whereas serum calcium [2.66 ± 0.3 vs 2.60 ± 0.23 (SD) mmol/l in Weeks 7-12 (P = 0.45) and 2.66 ± 0.23 (SD) mmol/l in Week 19-24 (P = 0.21)] and serum potassium [4.69 ± 0.48 vs 4.58 ± 0.68 (SD) mmol/l in Week 7-12 (P = 0.40) and 4.65 ± 0.49 (SD) mmol/l in Week 19-24 (P = 0.73)] remained unchanged. The mean daily PB dose rose from 6.3 ± 2.9 to 8.2 ± 5.4 (SD) pills during observation period with an increased meal-to-meal variability (P = 0.04). Dietary iP intake was not affected by PEP concept.
CONCLUSION: The empowerment of children with CKD and their parents to self-adjust PB dose to eye-estimated meal iP content significantly improved management of hyperphosphataemia without reducing dietary iP intake.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308040     DOI: 10.1093/ndt/gfq161

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.

Authors:  Maureen A Murtaugh; Rebecca Filipowicz; Bradley C Baird; Guo Wei; Tom Greene; Srinivasan Beddhu
Journal:  Nephrol Dial Transplant       Date:  2011-08-02       Impact factor: 5.992

2.  Barriers to medication adherence and its relationship with outcomes in pediatric dialysis patients.

Authors:  Douglas M Silverstein; Angela Fletcher; Kathleen Moylan
Journal:  Pediatr Nephrol       Date:  2014-02-26       Impact factor: 3.714

Review 3.  A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Authors:  Wendy L St. Peter; Lori D Wazny; Eric Weinhandl; Katie E Cardone; Joanna Q Hudson
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 4.  Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1.

Authors:  Wei Ling Lau; Maria H Festing; Cecilia M Giachelli
Journal:  Thromb Haemost       Date:  2010-07-20       Impact factor: 5.249

5.  Multidisciplinary Team versus a "Phosphate-Counting" App for Serum Phosphate Control: A Randomized Controlled Trial.

Authors:  Ana Cecilia Farfan-Ruiz; Daniel Czikk; Julie Leidecker; Tim Ramsay; Brendan McCormick; Kumanan Wilson; Deborah Zimmerman
Journal:  Kidney360       Date:  2020-12-15

6.  The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores.

Authors:  Janeen B León; Catherine M Sullivan; Ashwini R Sehgal
Journal:  J Ren Nutr       Date:  2013-02-08       Impact factor: 3.655

7.  Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks.

Authors:  Yoshiko Shutto; Michiko Shimada; Maiko Kitajima; Hideaki Yamabe; Mohammed S Razzaque
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

8.  The TRANSNephro-study examining a new transition model for post-kidney transplant adolescents and an analysis of the present health care: study protocol for a randomized controlled trial.

Authors:  Martin Kreuzer; Jenny Prüfe; Dirk Bethe; Charlotte Vogel; Anika Großhennig; Armin Koch; Martina Oldhafer; Marie-Luise Dierks; Urs-Vito Albrecht; Silvia Müther; Reinhard Brunkhorst; Lars Pape
Journal:  Trials       Date:  2014-12-23       Impact factor: 2.279

9.  Patient education for phosphorus management in chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh
Journal:  Patient Prefer Adherence       Date:  2013-05-03       Impact factor: 2.711

Review 10.  Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence.

Authors:  Adrian Covic; Anjay Rastogi
Journal:  BMC Nephrol       Date:  2013-07-18       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.